Showing results (1221-1230 of 1,351) with videos related to

Sort By:
Pageof 136
The Lancet. Microbe|December 4, 2023
Performance of clinical metagenomics in France: a prospective observational studyJacques Fourgeaud, Béatrice Regnault, Vichita Ok, et al.
Journal of Medicinal Chemistry|December 22, 2000
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitorsC Burnouf, E Auclair, N Avenel, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 18, 2010
[How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?]P Bigot, J-C Bernhard, M Crepel, et al.
Msphere|November 8, 2019
Insights into the Host Range, Genetic Diversity, and Geographical Distribution of JingmenvirusesSarah Temmam, Thomas Bigot, Delphine Chrétien, et al.
The EMBO Journal|July 18, 2024
Ezrin, radixin, and moesin are dispensable for macrophage migration and cellular cortex mechanicsPerrine Verdys, Javier Rey Barroso, Adeline Girel, et al.
Iscience|June 4, 2024
Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneityJudit Núñez-Manchón, Júlia Capó, Alicia Martínez-Piñeiro, et al.
Lancet (London, England)|October 20, 2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trialMaria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al.
Scientific Reports|November 8, 2022
Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study)A Ingels, K Bensalah, J B Beauval, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum ChemotherapyNatasha B Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, et al.
Cardiovascular and Interventional Radiology|June 23, 2026
Partial Nephrectomy Versus Thermal Ablation for Cystic Renal Tumors: A Registry-Based, Propensity Score Matched Analysis (UroCCR n°177)Gianpaolo Lucignani, Pierre Bigot, Morgan Roupret, et al.
Pageof 136